viewKazia Therapeutics Ltd

Kazia Therapeutics directors support company through entitlement offer participation

Proceeds form the entitlement offer will position Kazia as a late-stage global oncology company with a highly-compelling asset and a well-funded path to market.

Kazia Therapeutics Ltd - Kazia Therapeutics directors demonstrate faith in company's bio-technology by participating in entitlement offer
The entitlement offer is fully underwritten by Bell Potter Securities Limited

Kazia Therapeutics Ltd (ASX:KZA) directors have demonstrated their faith in the company’s bio-technology strategy by participating in the company’s entitlement offer.

The offer was completed on October 2 after raising $16.4 million to fund Kazia’s participation in the GBM AGILE pivotal study in glioblastoma.

This entitlement offer attracted strong support from institutional shareholders with all eligible accelerated holders participating, and an overall take-up by those parties of approximately 70%.

Change of director's interests 

Chairman and non-executive director Iain Ross acquired 125,000 shares at 80 cents each in a direct interest, increasing the total amount of securities held to 945,001 shares.

Chief executive officer and executive director James Garner acquired 62,500 shares, increasing his stake in a direct interest to 362,500 shares.

Non-executive director Steven Coffey also acquired 62,500 shares in an indirect interest, increasing the total number of securities held in that interest to 402,500 shares.

Non-executive director Bryce Carmine also purchased 62,500 shares increasing his total number of securities to 352,692 shares.

Quick facts: Kazia Therapeutics Ltd

Price: 1.355 AUD

Market: ASX
Market Cap: $128.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...


Kintara Therapeutics and Kazia Therapeutics begin trial to treat deadly...

Kintara Therapeutics Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive that its drug VAL-083 has been activated for an adaptive platform recurrent glioblastoma (GBM) trial. Zarrabian says Kintara, along with Kazia Therapeutics Limited (ASX:KZA) (NASDAQ:KZIA) and its drug paxalisib, will...

1 week, 3 days ago

2 min read